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Introduction: Colorectal cancer treatment requires a complex, multidisciplinary approach. Because of the potential
variability, monitoring through clinical audits is advisable. This study assesses the effects of a quality improvement
action plan in patients with locally advanced rectal cancer and treated with radiotherapy.
Methods: Comparative, multicentre study in two cohorts of 120 patients each, selected randomly from patients
diagnosed with rectal cancer who had initiated radiotherapy with a curative intent. Based on the results from a
baseline clinical audit in 2013, a quality improvement action plan was designed and implemented; a second audit
in 2017 evaluated its impact.
Results: Standardised information was present on 77.5% of the magnetic resonance imaging (MRI) staging reports.
Treatment strategies were similar in all three study centres. Of the patients whose treatment was interrupted, just
9.7% received a compensation dose. There was an increase in MRI re-staging from 32.5 to 61.5%, and a significant
decrease in unreported circumferential resection margins following neoadjuvant therapy (ypCRM), from 34.5 to
5.6% (p < 0.001).
Conclusions: The comparison between two clinical audits showed improvements in neoadjuvant radiotherapy in
rectal cancer patients. Some indicators reveal areas in need of additional efforts, for example to reduce the overall
treatment time.
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processIntroduction
Colorectal cancer is the third most common cancer
worldwide and the second in Catalonia; 45% of these tu-
mours are in the rectum [1, 2]. A locally advanced rectal
tumour (LART) is defined by the presence of a neoplasm
classified as T3/T4, with or without lymph node infiltra-
tion (N0/N+), and no metastatic dissemination. Treat-
ment is multidisciplinary and consists of surgery plus
radiochemotherapy [3], with careful evaluation of© The Author(s). 2020 Open Access This artic
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and after preoperative treatment. The total mesorectal
excision is a quality indicator, and the main factor for
local control, but in LART the neoadjuvant treatment
achieves greater control than surgery alone. Since the re-
sults of the Swedish Rectal Cancer Trial were published
in 1997 [4], neoadjuvant, multimodal treatment has
taken root as the standard treatment strategy. Substan-
tial reductions in local recurrence have been achieved
thanks to radiotherapy (RT), both short-course radio-
therapy (SCRT) and long-course radiotherapy (LCRT),
which is combined with chemotherapy. In historical
series, local recurrence was 30 to 45%, compared withle is distributed under the terms of the Creative Commons Attribution 4.0
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ment for LART also implies personalised strategies to
decrease the surgical burden for patients responding
after pre-operative treatment, including ‘wait and watch’
or organ-preservation approaches.
Thus, successful treatment of locally advanced rectal
cancer requires a multidisciplinary approach [6, 7]. The
complexity of care processes – and the resulting poten-
tial for variability in clinical decision-making – make
monitoring highly desirable. Clinical audits, for their
part, are a widely used instrument to identify variability
in clinical practice and areas in need of improvement.
Several countries have incorporated audits as a strategy
to evaluate health policies [8, 9]. The impact of the re-
sults obtained depends to a large extent on the analysis
of the outcomes, the quality of the data collected, and
the credibility of the audit team. There are few studies
that report the effects of corrective measures established
based on post-intervention audits [10].
The aim of this study was to assess the effects of the
quality improvement action plan on the quality of clin-
ical care processes in patients with rectal cancer, with an
emphasis on the diagnostic and neoadjuvant treatment
phases.
Methods
This study took place in the Institut Català d’Oncologia
(ICO), a cancer care organisation with three specialised
centres offering radiation oncology treatments. ICO col-
laborates with the corresponding university hospitals
that belong to the Institut Calatà de la Salut (ICS);it
works in a network with another 17 more local hospitals,
and it is the reference centre in oncology for nearly 3
million people (45% of the adult population in Catalo-
nia). The care model is characterised by a multidisciplin-
ary focus on specific pathologies, in compliance with
corporate clinical practice guidelines.
Study design
This multicentre comparative study was performed over
two periods (2013 and 2017). For each study year, we se-
lected a representative sample of patients diagnosed with
rectal cancer and treated with neoadjuvant RT.
The study began with the creation of a working group
made up of radiation oncologists and medical physicists
from all three centres, and led by the clinical reference
centre in rectal cancer. Key aspects of the diagnostic,
therapeutic and follow-up phases were identified based
on the literature [11, 12], as were the study indicators,
including the appropriateness of the diagnostic tests per-
formed, quality of the diagnostic reports, multidisciplin-
ary approach, appropriateness and adherence to the
prescribed treatment, imaging controls during the RT
sessions, post-surgical circumferential resection margin(ypCRM), and adverse effects. A purpose-designed form
was used to collect the required data during the first
audit, and for the second audit it was adapted to include
the new indicators derived from the action plan.
The first clinical audit for radiation oncology (ACOR-
1) identified areas in need of improvement. The analysis
of these published results [13] informed the develop-
ment of an action plan, which was approved in April
2016 and implemented thereafter. A new audit (ACOR-
2) was then performed to assess the extent to which the
improvement targets were achieved.
The audits consisted of a review of a random sample
of 40 clinical histories from each centre. The target
population was patients diagnosed with rectal cancer
(International Classification of Diseases; ICD-9:154.1)
who received neoadjuvant RT with a curative intent
(starting in 2013 in the first cohort and between June
and December of 2017 in the second).
For ACOR-2, the cognizant clinical practice guidelines
specified the criteria for concomitant chemotherapy and
two alternative strategies for RT: LCRT (45 Gy to 50.4
Gy in fractions of 1.8 Gy) and SCRT (25 Gy in fractions
of 5 Gy), administered on 5 consecutive days. The SCRT
strategy was preferentially indicated in patients over the
age of 70, in tumours of the middle third of the rectum,
and in disease without involvement of the mesorectal
fascia or metastasis [14].
Following a pilot test, a team of external auditors
undertook the first audit from June to September 2015,
and the second from June to September 2018. Data were
collected from the electronic clinical records in the par-
ticipating centres (SAP i.s.h. med Cerner & SAP) and
the specific information system for radiotherapy (Aria
oncology information System BY Varian Medical Sys-
tems Inc.).
Action plan
For the diagnostic phase, the quality improvement action
plan (Table 1) covered measures to increase the available
clinical information needed to develop a treatment strat-
egy, based on personal communication and multidiscip-
linary committees. The audit highlighted the need to
standardise the MRI report, based on the Mercury Study
Group criteria [15]. Another aspect considered was
tumour board review to approve the treatment plan, in
patients diagnosed both in our centres and in the re-
gional hospitals.
Measures to improve the treatment phase included
standardising the use of intensity-modulated radiother-
apy (IMRT) in the three centres, based on the following
indications: tumours in the lower third of the rectum;
patients with hysterectomy; rT4 rectal tumours; and
infiltration to the prostate, bladder or uterus in patients
in whom the planning target volume included the
Table 1 Description of action plan (approved 18 April 2016)
Area for improvement Target
Diagnostic phase
1 Increase availability of biopsy report > 95% availability of reports
2 Standardise MRI report > 85% of reports meet Mercury Study Group criteria* (ICS-IDI diagnostic imaging
service)
3 Increase multidisciplinary working (treatment strategy) > 85% of patients diagnosed at ICO have cases reviewed by tumour board
Treatment phase
1 Standardise criteria for indicating radiotherapy (IMRT)† > 85% of patients with indication for radiotherapy are treated with IMRT
2 Improve adherence to planned RT treatment (OTT)
Develop protocol for managing treatment interruptions Approve protocol by October 2016 and implement it
Disseminate and apply protocol Reduce % of patients with prolonged OTT
Reduce % of patients finalising treatment on Monday
3 Standardise criteria for imaging controls during treatment
Develop protocol for imaging controls during treatment
(IGRT)
Approve protocol by October 2016 and implement it
Disseminate and apply protocol > 85% of patients with imaging control according to protocol
4 Standardise anatomical pathology report (surgical
specimen): report ypCRM
> 85% of pathology reports note ypCRM
Follow-up phase
1 Report adverse effects according to severity, based on
CTCAE (v4.0) classifications
> 85% of follow-up visits record presence or absence of adverse events and their
CTCAE grade during the clinical course
CTCAE Common Terminology Criteria for Adverse Events, ICS Institut Català de la Salut, ICO Institut Català d’Oncologia, IDI Institut de Diagnòstic per la Imatge,
IGRT image-guided radiotherapy, IMRT intensity-modulated radiotherapy, MRI magnetic resonance imaging, OTT overall treatment time, ypCRM circumferential
resection margin (following neoadjuvant treatment)
aMercury Study Group criteria:
1) distance to anal verge and relationship between tumour and sphincter
2) infiltration beyond muscularis propia in mm
3) lymphatic state
4) extramural vascular spread
5) potential CRM invasion
6) presence of tumour implants
bIndication for IMRT according to patient profile:
1) tumour in lower third of rectum in which dosage to genitals should be reduced to V30 < 35%
2) rectal tumour in patients with hysterectomy (or laparotomy) in whom the dosage to the intestine exceeds V15 < 150 cc or V15 < 120 cc
3) rT4 rectal tumour with infiltration to prostate, urinary bladder or uterus, in whom the planning target volume includes lymphatic areas of the external
iliac system
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[16]. Other measures were the development and imple-
mentation of a management protocol for RT session in-
terruptions to reduce prolonged overall treatment time
(OTT) and a protocol for image-guided radiotherapy
(IGRT) during the treatment (to be undertaken at least
once a week); an increase in the percentage of patients
re-evaluated with MRI prior to surgery; and the state of
the ypCRM on the pathology report describing the sur-
gical specimens.
Finally, for the follow-up, the action plan aimed to im-
prove reporting of adverse effects over the clinical
course, according to the Common Terminology Criteria
for Adverse Events (CTCAE) v4.0 [17].
We used R software available as Free Software (version
3.0.2) for the statistical analysis. The sample size calcula-
tion was based on a level of confidence of 0.95 (α =
0.05), assuming a finite population of about 100 casesper centre and a 20% rate of attrition. Pearson’s chi-
squared test was used to compare results between
groups.Results
Table 2 presents the characteristics of the patients in-
cluded in the ACOR-1 and ACOR-2 cohorts. There were
no significant differences in the demographic or clinical
profiles, except in histological grade and distance from
tumour to mesorectal fascia. Table 3 shows the outcomes
for the diagnostic phase after implementing the action
plan. Availability of the biopsy report reached 100% in pa-
tients in the second period, as did MRI staging in two of
the three centres. The MRI reports met the established
criteria in 77.5% of the cases, representing a significant rise
with respect to the first period. In centre A, there were 10
cases where the report noted the distance from the
Table 2 Patient’s clinical characteristics



















Men 86 (71.7%) 85 (70.8%) > 0.99 29 (72.5%) 25 (62.5%) 0.47 27 (67.5%) 32 (80%) 0.31 30 (75%) 28 (70%) 0.80
Women 34 (28.3%) 35 (29.2%) 11 (27.5%) 15 (37.5%) 13 (32.5%) 8 (20%) 10 (25%) 12 (30%)
Age (years)
< 60 28 (23.3%) 42 (35%) 0.13 13 (32.5%) 12 (30%) 0.59 9 (22.5%) 15 (37.5%) 0.45 6 (15%) 15 (37.5%) 0.15
60–69 42 (35%) 37 (30.8%) 11 (27.5%) 13 (32.5%) 16 (40%) 12 (30%) 15 (37.5%) 12 (30%)
70–79 40 (33.3%) 28 (23.3%) 13 (32.5%) 9 (22.5%) 13 (32.5%) 10 (25%) 14 (35%) 9 (22.5%)




119 (99.2%) 120 (100%) > 0.99 40 (100%) 40 (100%) > 0.99 40 (100%) 40 (100%) > 0.99 39 (97.5%) 40 (100%) > 0.99
Squamous cell
carcinoma




43 (35.8%) 51 (42.5%) 0.37 9 (22.5%) 3 (7.5%) 0.01† 17 (42.5%) 18 (45%) 0.60 17 (42.5%) 30 (75%) 0.015†
Moderately
differentiated
20 (16.7%) 25 (20.8%) 3 (7.5%) 14 (35%) 7 (17.5%) 9 (22.5%) 10 (25%) 2 (5%)
Poorly
differentiated
4 (3.3%) 2 (1.7%) 1 (2.5%) 0 (0%) 0 (0%) 1 (2.5%) 3 (7.5%) 1 (2.5%)
NR 53 (44.2%) 42 (35%) 27 (67.5%) 23 (57.5%) 16 (40%) 12 (30%) 10 (25%) 7 (17.5%)
Distance from tumour to mesorectal fascia
≤ 1 mm 29 (24.2%) 43 (35.8%) 0.001‡ 9 (22.5%) 13 (32.5%) 0.24 14 (35%) 14 (35%) 0.07 6 (15%) 16 (40%) 0.01†
> 1mm 45 (37.5%) 56 (46.7%) 14 (35%) 17 (42.5%) 19 (47.5%) 25 (62.5%) 12 (30%) 14 (35%)
Not reported 46 (38.3%) 21 (17.5%) 17 (42.5%) 10 (25%) 7 (17.5%) 1 (2.5%) 22 (55%) 10 (25%)
Distance from tumour to anal verge
0–5 cm 24 (29.3%) 37 (35.9%) 0.51 2 (22.2%) 8 (32%) 0.15 13 (33.3%) 13 (33.3%) > 0.99 9 (26.5%) 16 (41%) 0.42
> 5–10 cm 41 (50%) 43 (41.7%) 7 (77.8%) 11 (44%) 15 (38.5%) 15 (38.5%) 19 (55.9%) 17 (43.6%)
> 10 cm 17 (20.7%) 23 (22.3%) 0 (0%) 6 (24%) 11 (28.2%) 11 (28.2%) 6 (17.6%) 6 (15.4%)
Stage
I 2 (1.7%) 0 (0%) 0.38 0 (0%) 0 (0%) 0.95 1 (2.5%) 0 (0%) 0.384 1 (2.5%) 0 (0%) 0.679
II 14 (11.7%) 10 (8.3%) 7 (17.5%) 6 (15%) 4 (10%) 1 (2.5%) 3 (7.5%) 3 (7.5%)
III 94 (78.3%) 97 (80.8%) 30 (75%) 31 (77.5%) 31 (77.5%) 34 (85%) 33 (82.5%) 32 (80%)
IV 10 (8.3%) 13 (10.8%) 3 (7.5%) 3 (7.5%) 4 (10%) 5 (12.5%) 3 (7.5%) 5 (12.5%)
ACOR clinical audit for radiation oncology, ICS Institut Català de la Salut, ICO Institut Català d’Oncologia, NR not reported
*p-value 0.05 to 0.01; †p-value ≤0.01; ‡p-value ≤0.001
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verge (these measures are considered equivalent with re-
spect to the fulfilment of the standard).
The outcomes for the treatment phase are detailed in
Table 4. The pattern of neoadjuvant treatment is similar
between centres and in both cohorts. In ACOR-2, 62.7%
of the patients received a total of 50.4 Gy (LCRT), a sig-
nificant difference with respect to ACOR-1 that mainly
reflects an improvement in centre A.
A protocol for managing treatment interruptions
was approved in June 2017. Compliance was 9.7%; wedid not observe a significant decrease in patients with
prolonged OTT over seven days (in the case of
LCRT) or in the percentage of patients who received
their last dose on a Monday (radiotherapy units are
not active on weekends). A protocol for image-guided
radiotherapy was approved in October 2016; the com-
pliance rate was 95.8%.
There was a significant increase in the performance
of the MRI restaging procedure in all centres, from
32.5 to 61.3% (Table 5). The proportion of patients in
whom surgery was indicated dropped slightly, from
Table 3 Action plan results: outcomes in diagnostic phase


















Was the patient diagnosed outside of ICO-ICS?
Yes 71 (59.2%) 100 (83.3%) < 0.001‡ 10 (25%) 29 (72.5%) < 0.001‡ 30 (75%) 37 (92.5%) 0.069* 31 (77.5%) 34 (85%) 0.57
No 49 (40.8%) 20 (16.7%) 30 (75%) 11 (27.5%) 10 (25%) 3 (7.5%) 9 (22.5%) 6 (15%)
In patients diagnosed in ICO-ICS, did a tumour board review the case?
Yes 39 (88.6%) 20 (100%) 0.29 25 (86.2%) 11 (100%) 0.48 10 (100%) 3 (100%) 0.052 4 (80%) 6 (100%) 0.92
No 5 (11.4%) 0 (0%) 4 (13.8%) 0 (0%) 0 (0%) 0 (0%) 1 (20%) 0 (0%)
In patients diagnosed outside of ICO-ICS, did a tumour board review the case?
Yes 34 (47.9%) 68 (68%) 0.019* 3 (30%) 17 (58.6%) 0.23 18 (60%) 35 (94.6%) 0.002 13 (41.9%) 16 (47.1%) 0.55
No 36 (50.7%) 32 (32%) 7 (70%) 12 (41.4%) 12 (40%) 2 (5.4%) 17 (54.8%) 18 (52.9%)
NR 1 (1.4%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (3.2%) 0 (0%)
Was the biopsy report in the medical history?
Yes 110 (91.7%) 120 (100%) 0.004† 37 (92.5%) 40 (100%) 0.24 37 (92.5%) 40 (100%) 0.24 36 (90%) 40 (100%) 0.12
No 10 (8.3%) 0 (0%) 3 (7.5%) 0 (0%) 3 (7.5%) 0 (0%) 4 (10%) 0 (0%)
Was the pelvic MRI recorded in the diagnostic report?
Yes 114 (95%) 119 (99.2%) 0.13 38 (95%) 40 (100%) 0.47 40 (100%) 40 (100%) > 0.99 36 (90%) 39 (97.5%) 0.36
No 6 (5%) 1 (0.8%) 2 (5%) 0 (0%) 0 (0%) 0 (0%) 4 (10%) 1 (2.5%)
Did the MRI report include information on the distance to the anal verge or to the anorectal union**?
Yes 82 (68.3%) 116 (96.7%) < 0.001‡ 9 (22.5%) 38 (95%) 0.001‡ 39 (97.5%) 39 (97.5%) > 0.99 34 (85%) 39 (97.5%) 0.12
No 38 (31.7%) 4 (3.3%) 31 (77.5%) 2 (5%) 1 (2.5%) 1 (2.5%) 6 (15%) 1 (2.5%)
Did the MRI report include information on the distance to the mesorectal fascia?
Yes 74 (61.7%) 99 (82.5%) < 0.001‡ 23 (57.5%) 30 (75%) 0.16 33 (82.5%) 39 (97.5%) 0.062 18 (45%) 30 (75%) 0.012*
No 46 (38.3%) 21 (17.5%) 17 (42.5%) 10 (25%) 7 (17.5%) 1 (2.5%) 22 (55%) 10 (25%)
Did the MRI report include enough information to assign a ‘T’ value?
Yes 112 (93.3%) 117 (98.3%) 0.11 37 (92.5%) 39 (97.5%) 0.61 39 (97.5%) 40 (100%) > 0.99 36 (90%) 38 (97.4%) 0.37
No 8 (6.7%) 2 (1.7%) 3 (7.5%) 1 (2.5%) 1 (2.5%) 0 (0%) 4 (10%) 1 (2.6%)
Did the MRI report include enough information to assign an ‘N’ value?
Yes 120 (100%) 118 (99.2%) > 0.99 40 (100%) 39 (97.5%) > 0.99 40 (100%) 40 (100%) > 0.99 40 (100%) 39 (100%) 0.91
No 0 (0%) 1 (0.8%) 0 (0%) 1 (2.5%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Did the MRI report meet Mercury Study Group criteria?
Yes 54 (45%) 93 (77.5%) < 0.001‡ 5 (12.5%) 27 (67.5%) < 0.001‡ 33 (82.5%) 38 (95%) 0.16 16 (40%) 28 (70%) 0.013*
No 66 (55%) 27 (22.5%) 35 (87.5%) 13 (32.5%) 7 (17.5%) 2 (5%) 24 (60%) 12 (30%)
ACOR clinical audit for radiation oncology, ICS Institut Català de la Salut, ICO Institut Català d’Oncologia, MRI magnetic resonance imaging, NR not reported
*p-value 0.05 to 0.01; †p-value ≤0.01; ‡p-value ≤0.001
**Centre A: 13 cases had the distance to the anorectal union (not to the anal verge)
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ing a conservative treatment strategy. There was also
a significant improvement in the availability of the
ypCRM on the anatomical pathology report (ACOR-2:
94.4%).
For the follow-up phase, adverse effects of treatment
were reported on 99.8% of the visits, and these were
graded for severity according to the CTCAE in 36.2% of
the cases.Discussion
Clinical audits are a well-known tool for identifying
areas to improve in the care process. This study reports
the results of an action plan for improving quality in
neoadjuvant treatment for locally advanced rectal cancer
in three centres, based on the findings of an initial qual-
ity audit. The ACOR-1 audit revealed variability in clin-
ical practice between centres and showed suboptimal
outcomes for several standard quality indicators. ACOR-
Table 4 Action plan results: outcomes in treatment phase I (neoadjuvant treatment)
























115 (95.8%) 107 (89.2%) 0.086 37 (92.5%) 34 (85%) 0.48 39 (97.5%) 39 (97.5%) > 0.99 39 (97.5%) 34 (85%) 0.11
RT 5 (4.2%) 13 (10.8%) 3 (7.5%) 6 (15%) 1 (2.5%) 1 (2.5%) 1 (2.5%) 6 (15%)
Type of radiotherapy
LCRT 108 (90%) 102 (85%) 0.33 36 (90%) 32 (80%) 0.35 40 (100%) 38 (95%) 0.47 32 (80%) 32 (80%) > 0.99
SCRT 12 (10%) 18 (15%) 4 (10%) 8 (20%) 0 (0%) 2 (5%) 8 (20%) 8 (20%)
Type of indicated technology
3D 117 (97.5%) 95 (79.2%) < 0.001‡ 40 (100%) 23 (57.5%) < 0.001‡ 40 (100%) 38 (95%) 0.47 37 (92.5%) 34 (85%) 0.48
VMAT 3 (2.5%) 25 (20.8%) 0 (0%) 17 (42.5%) 0 (0%) 2 (5%) 3 (7.5%) 6 (15%)
Total dosage administered
25 Gy 12 (10.3%) 18 (15.3%) 0.034* 4 (10.3%) 8 (21.1%) < 0.001‡ 0 (0%) 2 (5%) 0.36 8 (21.1%) 8 (20%) 0.57
45 Gy 34 (29.1%) 15 (12.7%) 34 (87.2%) 14 (36.8%) 0 (0%) 0 (0%) 0 (0%) 1 (2.5%)
50 Gy 3 (2.6%) 6 (5.1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 3 (7.9%) 6 (15%)
50.4 Gy 63 (53.8%) 74 (62.7%) 1 (2.6%) 16 (42.1%) 35 (87.5%) 33 (82.5%) 27 (71.1%) 25 (62.5%)
54 Gy 5 (4.3%) 5 (4.2%) 0 (0%) 0 (0%) 5 (12.5%) 5 (12.5%) 0 (0%) 0 (0%)
Prolongation of treatment time (if SCRT)
< 3 days 12 (100%) 17 (94.4%) > 0.99 4 (100%) 8 (100%) 0.25 0 (NaN%) 2 (100%) 0.16 8 (100%) 7 (87.5%) > 0.99
3–5 days 0 (0%) 1 (5.6%) 0 (0%) 0 (0%) 0 (NaN%) 0 (0%) 0 (0%) 1 (12.5%)
Prolongation of treatment time (if LCRT)
< 3 days 62 (57.4%) 58 (56.9%) 0.96 19 (52.8%) 20 (62.5%) 0.22 31 (77.5%) 27 (71.1%) 0.53 12 (37.5%) 11 (34.4%) 0.90
3–5 days 32 (29.6%) 31 (30.4%) 11 (30.6%) 10 (31.2%) 9 (22.5%) 9 (23.7%) 12 (37.5%) 12 (37.5%)
6–7 days 4 (3.7%) 5 (4.9%) 0 (0%) 1 (3.1%) 0 (0%) 1 (2.6%) 4 (12.5%) 3 (9.4%)
> 7 days 10 (9.3%) 8 (7.8%) 6 (16.7%) 1 (3.1%) 0 (0%) 1 (2.6%) 4 (12.5%) 6 (18.8%)
Week day when treatment was finalised
Monday 17 (14.2%) 7 (5.8%) 0.24 6 (15%) 1 (2.5%) 0.16 6 (15%) 3 (7.5%) 0.68 5 (12.5%) 3 (7.5%) 0.28
Tuesday 24 (20%) 22 (18.3%) 11 (27.5%) 11 (27.5%) 5 (12.5%) 6 (15%) 8 (20%) 5 (12.5%)
Wednesday 13 (10.8%) 12 (10%) 5 (12.5%) 5 (12.5%) 2 (5%) 1 (2.5%) 6 (15%) 6 (15%)
Thursday 24 (20%) 27 (22.5%) 8 (20%) 5 (12.5%) 11 (27.5%) 9 (22.5%) 5 (12.5%) 13 (32.5%)
Friday 42 (35%) 52 (43.3%) 10 (25%) 18 (45%) 16 (40%) 21 (52.5%) 16 (40%) 13 (32.5%)
ACOR clinical audit for radiation oncology, LCRT long-course radiotherapy, SCRT short-course radiotherapy, RT radiotherapy, VMAT volumetric modulated arc therapy
*p-value 0.05 to 0.01; †p-value ≤0.01; ‡p-value ≤0.001
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implementation of quality improvement measures.
In the diagnostic phase, the MRI is the best tool to
identify the patients with locally advanced tumours who
would most benefit from neoadjuvant treatment [14]. All
the cases audited in ACOR-2 included this test, and
there was a significant improvement in the quality of the
report. Specifically, there was an increase in adherence
to the Mercury Group’s recommendations on reporting
rectal cancer MRIs [15], including the distance from the
tumour to the mesorectal fascia (CRM), reported in
61.7% of the cases in ACOR-1 and 82.5% in ACOR-2,
and the distance to the anal verge or the anorectalunion, reported in 68.3 and 96.7% of the cases, respect-
ively (p < 0.001). Overall, the centres did not achieve
the optimal level of reporting (85%), but 77.5% of the re-
ports in ACOR-2 did meet the established criteria, com-
pared to just 45% in ACOR-1 – a significant change. We
consider that having a proforma, which would include
the state of the resection margin (CRM) and the distance
from the tumour to the anal verge, would be a decisive
factor in achieving optimal reporting, as described by
Taylor and colleagues [18, 19].
The number of patients coming to the ICO-ICS unit
with a diagnosis in hand increased significantly, probably
due to the centralisation policies implemented for this
Table 5 Action plan results: outcomes in treatment phase II (restaging and surgical treatment)


















Was the restaging report available?
Yes 39 (32.5%) 73 (61.3%) < 0.001‡ 0 (0%) 16 (40%) < 0.001‡ 31 (77.5%) 37 (94.9%) 0.057 8 (20%) 20 (50%) 0.01†
No 81 (67.5%) 46 (38.7%) 40 (100%) 24 (60%) 9 (22.5%) 2 (5.1%) 32 (80%) 20 (50%)
Did the patient undergo surgery?
Yes 116 (96.7%) 108 (90%) 0.035* 40 (100%) 33 (82.5%) 0.018* 37 (92.5%) 37 (92.5%) > 0.99 39 (97.5%) 38 (95%) 0.22
No 3 (2.5%) 12 (10%) 0 (0%) 7 (17.5%) 3 (7.5%) 3 (7.5%) 0 (0%) 2 (5%)
NR 1 (0.8%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (2.5%) 0 (0%)
Staging (in patients undergoing surgical treatment)
0 19 (16.4%) 20 (18.5%) 0.54 7 (17.5%) 5 (15.2%) 0.52 7 (18.9%) 9 (24.3%) 0.93 5 (12.8%) 6 (15.8%) 0.53
I 4 (3.4%) 3 (2.8%) 2 (5%) 1 (3%) 1 (2.7%) 1 (2.7%) 1 (2.6%) 1 (2.6%)
II 62 (53.4%) 47 (43.5%) 20 (50%) 12 (36.4%) 18 (48.6%) 19 (51.4%) 24 (61.5%) 16 (42.1%)
III 25 (21.6%) 28 (25.9%) 10 (25%) 12 (36.4%) 9 (24.3%) 6 (16.2%) 6 (15.4%) 10 (26.3%)
IV 6 (5.2%) 10 (9.3%) 1 (2.5%) 3 (9.1%) 2 (5.4%) 2 (5.4%) 3 (7.7%) 5 (13.2%)
ypCRM (in patients undergoing surgical treatment)
Positive 5 (4.3%) 16 (14.8%) < 0.001‡ 1 (2.5%) 4 (12.1%) < 0.001‡ 3 (8.1%) 3 (8.1%) 0.037* 1 (2.6%) 9 (23.7%) 0.006†
Negative 71 (61.2%) 86 (79.6%) 15 (37.5%) 26 (78.8%) 28 (75.7%) 34 (91.9%) 28 (71.8%) 26 (68.4%)
NR 40 (34.5%) 6 (5.6%) 24 (60%) 3 (9.1%) 6 (16.2%) 0 (0%) 10 (25.6%) 3 (7.9%)
ACOR clinical audit for radiation oncology, NR not reported
*p-value 0.05 to 0.01; †p-value ≤0.01; ‡p-value ≤0.001
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the ICO unit were reviewed by a tumour board to ap-
prove the therapeutic strategy.
In ACOR-2, the treatment plan adopted most fre-
quently was radiochemotherapy, with LCRT and a dose
of 50.4 Gy. Compared with the outcomes observed in
ACOR-1, ACOR-2 showed greater standardisation be-
tween centres and better adherence to the approved
guidelines, although some variability persists, which is
consistent with other studies [21]. For example, two of
the centres used SCRT in 20% of the patients, while the
other did so in just 5%. This difference is probably due
to the divergent approaches in patients of advanced age.
One centre adheres to the strategy for avoiding surgery
in frail patients, so its adoption of LCRT is more assidu-
ous. In contrast, the other two centres favour the avoid-
ance of chemotherapy [22, 23].
We also noted an increase in the use of volumetric
modulated arc therapy (VMAT), from 2.5 to 20.8%
(p < 0.001), and its dissemination in all three centres.
Although the radiated intestinal volume may be
susceptible to late toxicity, VMAT reduces acute toxicity
and consequently, treatment interruptions [16]. Thus,
consensus-based indications were developed for patients
with tumours that infiltrated into adjacent organs, and
in general when treatment of the external iliac lymph
nodes and/or the groin nodes is unavoidable.One of the action plan’s target areas was OTT. Even
though special efforts were made to improve this indica-
tor, both audits showed that the overall RT treatment
time was still more than seven days longer than planned
for LCRT, usually because of weekday public holidays
and technical inspections of the accelerators. There were
no significant changes between study periods. We also
observed a non-significant improvement in the percent-
age of patients whose last RT session was on a Monday.
To improve this aspect, a protocol for managing treat-
ment interruptions was designed and finally approved in
June 2017. The delay in approval is probably the reason
that we identified only seven patients in whom it was ap-
propriately applied (four of them in centre B). Indeed,
the included patients initiated treatment only from June
to December 2017. Thus, the centres still have work to
do in improving adherence to the treatment. As with
any measure that affects the daily work routine and en-
tails organisational changes, achieving success in this en-
deavour will be challenging [24].
Another target area was the standardisation of IGRT
during treatment. This measure, too, was subject to a
new protocol (approved in October 2016), and adher-
ence was 95.8%.
Once the neoadjuvant treatment is finalised, restaging
(primarily based on MRI) is necessary to define the sur-
gical technique. We observed a significant rise in the
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32.5% of all cases undergoing MRI restaging in ACOR-1
and 61.3% in ACOR-2 (p < 0.001). Moreover, there is
already a consolidated scientific basis permitting selected
patients to follow a conservative strategy and avoid sur-
gery, that is, ‘watch and wait’ [25, 26]. In our case, in
ACOR-2, surgery was indicated in 90% of the patients,
compared to 96.7% in ACOR-1 (p = 0.035). In 3/12
patients (25%) in whom surgery was not indicated,
the reason was having cT0N0 after completing
chemoradiotherapy.
Without a doubt, the most important quality indicator
in neoadjuvant treatment of rectal cancer for local con-
trol and survival is the state of the circumferential resec-
tion margin (ypCRM). This detail was not described in
the anatomical pathology report for 34.5% of the surgical
specimens in ACOR-1, compared to 5.6% in ACOR-2
(p < 0.001). Overall, 14.8% of the surgical specimens
showed CRM involvement (ypCRM+), which is consist-
ent with the literature [27, 28]. Considering the RT strat-
egy, 13% of the LCRT treatments had ypCRM+,
compared to 25% of those with SCRT treatment. We
considered the proportion of 10% to be optimal.
With regard to the low-quality reporting of adverse
events over the clinical course (absence of grading and
aspects related to sexual function or bowel control), the
specific list of CTCAE (v 4.0) criteria [15] helped to
moderately improve reporting. Nevertheless, the results
obtained in ACOR-2 highlight the need to double down
on efforts to improve this aspect.
The ultimate aim of treatment is not only to cure dis-
ease, but also to restore the person’s dignity and achieve
their social reinsertion. To this end, it is essential to
understand the impact of dysfunctions and symptoms
derived from treatment on patients’ quality of life [29].
Future studies are necessary to explore this aspect in the
long term, applying specific validated instruments like
the EORTC questionnaires for quality of life in cancer
patients and for colorectal quality of life in patients with
rectal cancer receiving neoadjuvant treatment.
This study has several limitations. Some are related to
the design of the audit, which included only 40 clinical
histories per centre, limiting the power of the assess-
ment, especially for clinical outcomes. In addition, the
period selected (especially for the ACOR-2) allowed little
time for the consolidation of changes derived from the
action plan. Moreover, the data collected were from clin-
ical histories; any measure taken but not recorded on
the patient’s electronic medical record would, for the
purposes of the clinical audit, be non-existent.
In conclusion, this study analyses the influence of
feedback from clinical audit data in improving neoadju-
vant treatment procedures in rectal cancer. Our results
show progress as well as areas in which additional effortsshould be made, including: decreasing the percentage of
positive ypCRMs; limiting treatment interruptions in
order to reduce overall treatment time; and better selec-
tion of therapeutic options in elderly patients, according
to frailty and mobility. In short, the audit undertaken
shows total or partial correction in most areas targeted
for quality improvements following the first audit, a de-
crease in variability between centres, and an improve-
ment in adherence to clinical practice guidelines for
rectal cancer.
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